Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Methoxy polyethelene glycol-epoetin beta (Mircera)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323.
Methylphenidate M/R tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	Specialist initiation only, ESCA
Methylphenidate tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Methylphenidate tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Mexiletine 167mg hard capsules (Namuscla®)	TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
Midostaurin	TA523 - Midostaurin for untreated acute myeloid leukaemia TA738 - Midostaurin for treating advanced systemic mastocytosis	For hospital use only
Mifamurtide	TA235 - Mifamurtide for the treatment of osteosarcoma	For hospital use only
Mifamurtide injection	TA235 - Mifamurtide for the treatment of osteosarcoma	For hospital use only
Migalastat (Galafold)	HST4 - Migalastat for treating Fabry disease
Mirabegron	TA290 - Mirabegron for treating symptoms of overactive bladder

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.